SPONSOR
Tasly Pharmaceutical Group Co., Ltd
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2, Phase 3
Tasly Pharmaceutical Group Co., Ltd is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Recurrent Glioblastoma IDH Wildtype, Ankylosing Spondylitis.
The trial portfolio spans Phase 1, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Tasly Pharmaceutical Group Co., Ltd
How many clinical trials has Tasly Pharmaceutical Group Co., Ltd sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Tasly Pharmaceutical Group Co., Ltd, of which 2 are actively recruiting participants. These trials cover conditions including Recurrent Glioblastoma IDH Wildtype, Ankylosing Spondylitis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Tasly Pharmaceutical Group Co., Ltd research focus on?
Tasly Pharmaceutical Group Co., Ltd clinical trials span Recurrent Glioblastoma IDH Wildtype, Ankylosing Spondylitis. The research pipeline includes Phase 1, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Tasly Pharmaceutical Group Co., Ltd clinical trial?
To participate in a Tasly Pharmaceutical Group Co., Ltd trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Tasly Pharmaceutical Group Co., Ltd trials with current recruitment status updated daily.
Clinical Trials by Tasly Pharmaceutical Group Co., Ltd
NCT07318818 Phase 1, Phase 2
Recruiting
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
Recurrent Glioblastoma IDH Wildtype
NCT06000956 Phase 3
Recruiting
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo
Ankylosing Spondylitis
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology